Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
" L, x: u! O; [4 M' N4 Z6 U, F. E, }) H/ g1 Z
! x+ A& g, c) e/ s. ~0 mSub-category:; f% a( m: g+ ~0 K3 u' x. N
Molecular Targets
1 F% X/ J2 a; f. ]
: W6 B6 N' `9 M, _5 @) U) \1 _% j( @# k' \+ n- ~
Category:8 b+ n: E- r& n1 J
Tumor Biology 5 @/ w" i* A& r% p1 m+ r
- X& X) e8 ~2 A& G0 Z
1 Z. z% C1 r8 |" k& [, b# F. f/ t% LMeeting:
$ h5 V/ u3 m% z0 P2011 ASCO Annual Meeting 0 q6 Q$ g% `2 f1 U+ x. n- j& \) n* m
m4 e, a& K1 Z
6 S) H+ O9 I9 Q& F6 R
Session Type and Session Title:
+ I# V* C' T5 z F- `: O7 n+ dPoster Discussion Session, Tumor Biology
. n# q% v- v/ _# J2 a
% P# }% B1 t" T. h* k
/ v/ S$ w! {* t3 O2 CAbstract No:# \7 V! Y, j* r( M
10517 3 x3 n, m' t* ?0 t b" ?
# {. ~8 e6 v: \' M$ g( `
5 i' _/ z+ B! u/ c% q P# OCitation:3 s# L8 Z9 s4 z( j
J Clin Oncol 29: 2011 (suppl; abstr 10517) & C+ O8 b/ @9 x8 U3 }! v/ V
9 _+ [7 o6 l( K
1 ~* `9 s$ }) ?5 I; a3 ?Author(s):7 I7 z! W% V, [" M: T7 M! i
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ' O$ ]6 k1 |" R6 C' c
' i4 t% G7 Y# `/ F- O% H
* `# w% o% z1 X) Q" r1 ?' t, |1 ^" w; B' y* A% o6 K1 w* K
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
- X4 z3 ~6 t/ L
* v3 c8 g9 l. S# j) U6 a. hAbstract Disclosures" f* \' Y- b0 C) @. D
8 R6 W! P7 _) H3 H
Abstract:' @/ X v1 `2 B# K& Y
" h! [9 R% @. b+ Z$ W
3 g3 \7 p' ~* T9 r G% ^4 t
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.* a, ^, a4 P, [+ d4 p1 X/ [3 r
* ?; G. t/ i! j! w: v/ I
' p3 ?" q6 g, ^$ H4 Y# ^; a
|
9 Q1 V$ u1 u$ \# ?8 J, q
显身卡
